Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\nWegovy Pill Data Shows Mixed Profile<\/p>\n
At the Obesity Medicine Association\u2019s annual meeting in San Diego, Novo Nordisk presented findings from its ORION study. A population-adjusted indirect comparison analysis indicated that its oral Wegovy tablet (semaglutid 25 mg) achieved approximately 3.2 percentage points more weight loss than Lilly\u2019s 36 mg Orforglipron. The data also suggested that patients discontinued Orforglipron treatment due to gastrointestinal side effects 14 times more frequently.<\/p>\n
However, this analysis relies solely on previously published study data and does not introduce new clinical evidence. A significant practical drawback remains: patients taking the Wegovy pill must wait 30 minutes before eating or drinking each day\u2014a restriction that does not apply to Lilly\u2019s Foundayo.<\/p>\n
Pipeline and Prescription Trends Under Scrutiny<\/p>\n
The combined drug CagriSema, a weekly injection of cagrilintid and semaglutid, represents Novo Nordisk\u2019s most important regulatory milestone ahead of its Capital Markets Day in September 2026. J.P. Morgan has lowered its revenue projections for the Novo Nordisk group for the period 2026-2030 by 2% to 16%, explicitly pointing to weak CagriSema study results as a key reason.<\/p>\n
The company\u2019s shares currently trade about 28% below their level at the start of the year, a significant retreat from their 52-week high. In the short term, weekly prescription data for the Wegovy pill will likely serve as a crucial indicator. Some market observers are already noting signs that physicians may be holding back on new prescriptions, possibly waiting to see initial market performance data for Lilly\u2019s Foundayo before making decisions.<\/p>\n
Ad<\/p>\n
Novo Nordisk Stock: New Analysis – 5 April<\/p>\n
Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n
Read our updated Novo Nordisk analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk releases Wegovy pill data ahead of Lilly’s launch as analysts cut targets citing competition and pipeline…\n","protected":false},"author":2,"featured_media":55492,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[949,9853,24485,5691,3845,272,13590,22886,4408,1910,280],"class_list":["post-55491","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug","tag-faces","tag-moment","tag-nordisk","tag-novo","tag-novo-nordisk","tag-oral","tag-pivotal","tag-race","tag-wegovy","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116350566005709829","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/55491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=55491"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/55491\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/55492"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=55491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=55491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=55491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}